Partnership Potential Turbine recently partnered with Ono Pharmaceutical Co., demonstrating a willingness to collaborate and explore new opportunities for joint research and development in the field of oncology targets.
Financial Growth With a recent infusion of $6.01M in Series A funding and substantial revenue in the range of $10M - 50M, Turbine is in a financially stable position to consider investing in innovative solutions and expanding its operations.
Leadership Addition The appointment of Bob Silverman as Chief Business Officer brings valuable industry experience to Turbine, potentially opening doors for strategic partnerships and market expansion under new leadership.
Innovative Strategies Developing novel patient selection strategies for CDC7 inhibitor compounds showcases Turbine's commitment to innovation and differentiation in the biopharma industry, attracting interest from potential collaborators looking for cutting-edge solutions.
Industry Recognition Having received significant funding in rounds like the $22.6M Series A financing, Turbine has garnered attention and credibility in the market, positioning itself as a strong player for partnerships and sales opportunities within the biotechnology research sector.